Latest Insider Transactions at Crinetics Pharmaceuticals, Inc. (CRNX)
This section provides a real-time view of insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Crinetics Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Crinetics Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2025
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
97,483
-49.43%
|
$3,119,456
$32.23 P/Share
|
|
Jun 12
2025
|
Stephen F. Betz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
88,170
+18.08%
|
$440,850
$5.6 P/Share
|
|
Jun 11
2025
|
Wendall Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+5.61%
|
-
|
|
Jun 11
2025
|
Weston Nichols |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Camille L Bedrosian |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+19.31%
|
-
|
|
Jun 11
2025
|
Coelho Rogerio Vivaldi |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+24.47%
|
-
|
|
Jun 11
2025
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
May 14
2025
|
Richard Scott Struthers President & CEO |
BUY
Bona fide gift
|
Indirect |
90,400
+12.03%
|
-
|
|
May 14
2025
|
Richard Scott Struthers President & CEO |
SELL
Bona fide gift
|
Direct |
90,400
-22.03%
|
-
|
|
Apr 02
2025
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
81,270
+16.53%
|
$81,270
$1.91 P/Share
|
|
Mar 19
2025
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
17,338
-2.51%
|
$589,492
$34.5 P/Share
|
|
Mar 19
2025
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,770
-2.53%
|
$196,180
$34.5 P/Share
|
|
Mar 19
2025
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,162
-3.8%
|
$243,508
$34.5 P/Share
|
|
Mar 19
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
2,515
-1.69%
|
$85,510
$34.5 P/Share
|
|
Mar 10
2025
|
Tobin Schilke Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+50.0%
|
-
|
|
Feb 20
2025
|
Stephen F. Betz Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+27.33%
|
-
|
|
Feb 20
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+36.52%
|
-
|
|
Feb 20
2025
|
Jeff E. Knight Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+31.24%
|
-
|
|
Feb 20
2025
|
Richard Scott Struthers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
89,000
+20.44%
|
-
|
|
Feb 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
5,000
-13.61%
|
$195,000
$39.07 P/Share
|
|
Feb 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.98%
|
$80,000
$16.89 P/Share
|
|
Jan 07
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.3%
|
$47,500
$19.64 P/Share
|
|
Jan 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
15,000
-33.9%
|
$780,000
$52.09 P/Share
|
|
Jan 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.32%
|
$240,000
$16.89 P/Share
|
|
Dec 16
2024
|
Stephen F. Betz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,331
+3.16%
|
$2,331
$1.91 P/Share
|
|
Dec 02
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
10,000
-9.09%
|
$570,000
$57.57 P/Share
|
|
Nov 22
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
501
-0.96%
|
$28,056
$56.52 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-33.52%
|
$776,250
$54.63 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.11%
|
$230,000
$16.89 P/Share
|
|
Sep 26
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
25,000
-18.37%
|
$1,275,000
$51.11 P/Share
|
|
Sep 26
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.52%
|
$375,000
$15.29 P/Share
|
|
Sep 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,035
-1.49%
|
$52,785
$51.5 P/Share
|
|
Aug 26
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-4.13%
|
$159,000
$53.19 P/Share
|
|
Aug 12
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.97%
|
$141,000
$47.68 P/Share
|
|
Jul 25
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.82%
|
$159,000
$53.43 P/Share
|
|
Jul 25
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
19,056
-14.64%
|
$1,009,968
$53.88 P/Share
|
|
Jul 25
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,056
+12.77%
|
$171,504
$9.28 P/Share
|
|
Jul 15
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,000
-34.33%
|
$1,485,000
$55.0 P/Share
|
|
Jul 15
2024
|
Jeff E. Knight Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,073
+10.18%
|
$547,533
$21.21 P/Share
|
|
Jul 15
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
25,000
-18.37%
|
$1,375,000
$55.0 P/Share
|
|
Jul 15
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.52%
|
$500,000
$20.02 P/Share
|
|
Jul 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.68%
|
$144,000
$48.55 P/Share
|
|
Jul 05
2024
|
James Hassard Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-33.89%
|
$660,000
$44.08 P/Share
|
|
Jul 05
2024
|
James Hassard Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.31%
|
$285,000
$19.73 P/Share
|
|
Jul 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-33.52%
|
$632,500
$44.87 P/Share
|
|
Jul 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.11%
|
$230,000
$16.89 P/Share
|
|
Jun 28
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
32,129
-22.43%
|
$1,381,547
$43.61 P/Share
|
|
Jun 28
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,129
+18.32%
|
$289,161
$9.28 P/Share
|